VIRUS INACTIVATION OF HUMAN BLOOD BEFORE CLINICAL ASSAYS

描述：本提案的目的是制定一个切实可行的 临床用血液样品中病毒灭活的方法 实验室测试该方法代表了一个重要的商业 机会，并适用于受以下物质污染的标本 致病病毒如HIV或丙型肝炎（HCV）。 病毒灭活 是通过一类新型的药物InactineSTM实现的， 对于核酸，不改变血液学和临床 化学分析初步研究表明， InactineSTM预防委内瑞拉马脑炎、埃博拉病毒和 其他病毒高达2个日志/小时。血清酶和血液学 测试保存在有效灭活的条件下， 这些病毒。在这个提案中，一系列的InactineSTM将被 用于真空采血管。最活跃的化合物 将使用标准化测定和最佳条件进行选择 用于在人血清和全血中测定的灭活。 将定义HIV的灭活动力学，并将定义HIV的模型病毒。 丙肝病毒。最后，血液学和临床化学的稳定性 将在最佳条件下测量血液样本中的分析 用于病毒灭活。 拟定商业应用： 商业应用是用于灭活 实验室用真空采血管采集的血液 分析.其目标是提高 负责处理血液的员工

DESCRIPTION: The objective of this proposal is to develop a practical method for virus inactivation in blood samples for clinical laboratory testing. The method represents a significant commercial opportunity and is applicable to specimens contaminated with pathogenic viruses like HIV or hepatitis C (HCV). Viral inactivation is achieved by a novel class of agents, InactineSTM, highly selective for the nucleic acid, that do not modify hematological and clinical chemistry analyses. Preliminary studies have shown that certain InactineSTM inactivate Venezuelan equine encephalitis, Ebola, and other viruses at up to 2 logs/hour. Serum enzymes and hematological tests were preserved under conditions that efficiently inactivated these viruses. In this proposal, a series of InactineSTM will be synthesized for use in vacuum blood tubes. The most active compound will be selected using a standardized assay, and optimal conditions for inactivation determined in human serum and whole blood. Inactivation kinetics will be defined for HIV and a model virus for HCV. Finally, the stability of hematological and clinical chemistry analyses in blood samples will be measured under optimal conditions for viral inactivation. PROPOSED COMMERCIAL APPLICATION: The commercial application is for the inactivation of viruses in blood collected in evacuated blood collection tubes for laboratory analysis. The goal is to provide an increased level of safety for the employees who will be handling and processing the blood.